Neoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference

Rhea-AI Summary

Neoleukin Therapeutics (NASDAQ:NLTX) is set to present at the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 1 p.m. Eastern Time. The presentation will feature CEO Jonathan Drachman, M.D., and will be available via webcast on the Neoleukin website. An archived replay will be accessible for 30 days post-event. Neoleukin specializes in developing advanced immunotherapies for cancer and autoimmunity using de novo protein design technology, with lead candidate NL-201 aiming to improve therapeutic tolerability.

SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the Canaccord Genuity 42^nd Annual Growth Conference on Wednesday, August 10, 2022 at 1 p.m. Eastern.

The webcast presentation can be accessed from the investors section of the Neoleukin website at http://investor.neoleukin.com/events. An archived replay will also be available on the company website for at least 30 days following the event.

About Neoleukin Therapeutics, Inc.

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com.

Contacts:

Media
Julie Rathbun
206-769-9219
jrathbun@neoleukin.com

Investors
Solebury Trout
Alexandra Roy
617-221-9197
aroy@soleburytrout.com

FAQ

When will Neoleukin Therapeutics present at the Canaccord Genuity 42nd Annual Growth Conference?

Neoleukin Therapeutics will present on August 10, 2022, at 1 p.m. Eastern Time.

Who will represent Neoleukin Therapeutics at the conference?

CEO Jonathan Drachman, M.D. will represent Neoleukin Therapeutics at the conference.

How can I access the Neoleukin Therapeutics conference presentation?

The webcast presentation can be accessed from the investors section of the Neoleukin website.

What is Neoleukin Therapeutics' lead product candidate?

Neoleukin's lead product candidate is NL-201, designed as a combined IL-2 and IL-15 agonist.

What types of therapies does Neoleukin Therapeutics focus on?

Neoleukin Therapeutics focuses on next-generation immunotherapies for cancer, inflammation, and autoimmunity.